U.S. Policy Support and Supply Chain Stability Bolster Respiris RPM Expansion

Respiri Limited (ASX: RSH) is set to benefit from growing U.S. policy momentum supporting AI-driven telehealth solutions. U.S. Health Secretary Robert F. Kennedy Jr. recently praised virtual care technologies as essential for improving access and quality of care—especially in rural communities—perfectly aligning with Respiri’s Connected Care and remote patient monitoring (RPM) strategy. This endorsement strengthens the company’s position as it partners with ACOs and other healthcare providers across the United States. 

In addition, recent U.S. tariffs on Chinese-manufactured medical devices will have minimal impact on Respiri’s operations due to its robust inventory of wheezo units in the country. The company has committed to absorbing any minor cost increases, ensuring uninterrupted service and pricing for customers. This strategic positioning, supported by effective supply chain planning and favorable policy trends, reinforces Respiri’s growth path and commitment to improving chronic care management nationwide.


 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com